

Brenntag SE: Release of a capital market information

Disclosure according to art. 5 para. 1 lit. b) and para. 3 of the Regulation (EU) no. 596/2014 in connection with art. 2 para. 3 of the Delegated Regulation (EU) no. 2016/1052

Share buyback - 31st Interim Report

Essen – January 8, 2024 – In the period from January 2, 2024 until and including January 5, 2024 a number of 251,211 shares were bought back within the framework of the share buyback program of Brenntag SE; disclosed by Brenntag SE on March 13, 2023 pursuant to art. 5 para. 1 lit. a) of the Regulation (EU) no. 596/2014 and art. 2 para. 1 of the Delegated Regulation (EU) no. 2016/1052 and which started on March 13, 2023.

The number of shares bought back daily and the daily volume-weighted average share prices are as follows:

Day of repurchase	Aggregated volume (number of shares)	Volume-weighted average share price (EUR)
02/01/2024	24,711	83.0749
03/01/2024	73,425	82.0731
04/01/2024	71,140	82.2165
05/01/2024	81,935	81.5637

The transactions in a detailed form are published on the website of Brenntag SE at <https://corporate.brenntag.com/en/investor-relations/brenntag-share/share-buyback-2023/>.

The total volume of shares which have been bought back within the framework of the share buyback program in the period from March 13, 2023 until and including January 5, 2024 amounts to a number of 7,297,374 shares.

The purchase of the shares of Brenntag SE is carried out by a credit institution that has been commissioned by Brenntag SE; the shares are purchased on the electronic trading platform of the Frankfurt Stock Exchange (Xetra).

Contact

Brenntag SE

Thomas Altmann, Senior Vice President Corporate Investor Relations

Phone: +49 201 6496 2100

thomas.altmann@brenntag.com

Brenntag SE

Messeallee 11
45131 Essen
P.O. Box 10 04 61
45004 Essen
Germany

Phone +49 201 64960
Fax +49 201 64961010
infobrenntag@brenntag.de
www.brenntag.com

Registered Domicile:
Essen
District Court:
Essen HRB 31943

Board of Management: Dr. Christian Kohlpaintner (Chairman),
Dr. Kristin Neumann, Michael Friede, Ewout van Jarwaarde
Supervisory Board Chairman:
Richard Ridinger